TY  - JOUR
AU  - Cebrián, Arancha
AU  - Gómez Del Pulgar, Teresa
AU  - Méndez-Vidal, María José
AU  - Gonzálvez, María Luisa
AU  - Lainez, Nuria
AU  - Castellano, Daniel
AU  - García-Carbonero, Iciar
AU  - Esteban, Emilio
AU  - Sáez, Maria Isabel
AU  - Villatoro, Rosa
AU  - Suárez, Cristina
AU  - Carrato, Alfredo
AU  - Munárriz-Ferrándiz, Javier
AU  - Basterrechea, Laura
AU  - García-Alonso, Mirta
AU  - González-Larriba, José Luis
AU  - Perez-Valderrama, Begoña
AU  - Cruz-Jurado, Josefina
AU  - González Del Alba, Aránzazu
AU  - Moreno, Fernando
AU  - Reynés, Gaspar
AU  - Rodríguez-Remírez, María
AU  - Boni, Valentina
AU  - Mahillo-Fernández, Ignacio
AU  - Martin, Yolanda
AU  - Viqueira, Andrea
AU  - García-Foncillas, Jesús
PY  - 2017
DO  - 10.1038/srep41371
UR  - http://hdl.handle.net/10668/10802
T2  - Scientific reports
AB  - Sunitinib is the currently standard treatment for metastatic renal cell carcinoma (mRCC). Multiple candidate predictive biomarkers for sunitinib response have been evaluated but none of them has been implemented in the clinic yet. The aim of this...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Biomarkers, Tumor
KW  - Carcinoma, Renal Cell
KW  - Cyclooxygenase 2
KW  - Disease-Free Survival
KW  - Female
KW  - Gene Frequency
KW  - Genetic Association Studies
KW  - Humans
KW  - Indoles
KW  - Kaplan-Meier Estimate
KW  - Kidney Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Models, Genetic
KW  - Multivariate Analysis
KW  - Polymorphism, Single Nucleotide
KW  - Pyrroles
KW  - Sunitinib
KW  - Treatment Outcome
TI  - Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.
TY  - research article
VL  - 7
ER  -